Product Pathways - Apoptosis
DR5 (D4E9) XP® Rabbit mAb #8074
|8074S||100 µl (10 western blots)||---||In Stock||---|
|8074P||40 µl (4 western blots)||---||In Stock||---|
|8074||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human||Endogenous||40, 48||Rabbit IgG|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation, IF-IC=Immunofluorescence (Immunocytochemistry)
Specificity / Sensitivity
DR5 (D4E9) XP® Rabbit mAb recognizes endogenous levels of total DR5 protein. This antibody detects both the short and long isoforms of DR5.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg260 within the cytoplasmic region of human DR5 protein.
Western blot analysis of extracts from various cell lines using DR5 (D4E9) XP® Rabbit mAb.
Western blot analysis of extracts from A549 cells, untreated or doxorubicin-treated (500 nM) for the indicated times, using DR5 (D4E9) XP® Rabbit mAb.
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with the long isoform of human DR5 (hDR5, +), using DR5 (D4E9) XP® Rabbit mAb.
The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5, and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL, and TRAIL. They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC), resulting in activation of caspases.
DR5 is a receptor for TNF-related apoptosis inducing ligand (TRAIL), which has been shown to induce apoptosis in a variety of cell types and has been targeted for cancer therapy (1-5). Structurally, DR5 contains an amino-terminal leader cleavage site, followed by an extracellular region containing two cysteine-rich repeats, a central transmembrane domain, and a carboxy-terminal DD. DR5 is expressed in a wide variety of tissues and is a transcriptional target of p53 (6-8). It induces apoptosis through a FADD-dependent pathway. Deletion of DR5 leads to resistance in TRAIL-mediated apoptosis as well as an abrogated response to DNA-damaging stimuli (9). At least two isoforms of DR5 are produced by alternative splicing (10).
- Nagata, S. (1997) Cell 88, 355-365.
- Thorburn, A. (2004) Cell. Signal. 16, 139-144.
- Wiley, S.R. et al. (1995) Immunity 3, 673-82.
- Walczak, H. et al. (1997) EMBO J 16, 5386-97.
- Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
- MacFarlane, M. et al. (1997) J Biol Chem 272, 25417-20.
- Wu, G.S. et al. (2000) Adv Exp Med Biol 465, 143-51.
- Wu, G.S. et al. (1997) Nat Genet 17, 141-3.
- Finnberg, N. et al. (2005) Mol Cell Biol 25, 2000-13.
- Screaton, G.R. et al. (1997) Curr Biol 7, 693-6.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
DRAQ5 is a registered trademark of Biostatus Limited.
XP is a registered trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.